#JPM24: GSK to buy asthma biotech Aiolos Bio for up to $1.4B three months after startup emerged

SAN FRANCISCO – GSK will pay $1 billion upfront to buy clinical-stage asthma drugmaker Aiolos Bio, the British drugmaker said early Tuesday morning. It could pay up to $400 million more if milestones are met.

The deal marks one of the quickest startup unveiling-to-buyout journeys in…
Click here to view original post